Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Income from Continuing Operations: 2016-2025

Historic Income from Continuing Operations for Collegium Pharmaceutical (COLL) over the last 10 years, with Sep 2025 value amounting to $31.5 million.

  • Collegium Pharmaceutical's Income from Continuing Operations rose 237.51% to $31.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.4 million, marking a year-over-year decrease of 34.03%. This contributed to the annual value of $42.4 million for FY2024, which is 7.88% down from last year.
  • Latest data reveals that Collegium Pharmaceutical reported Income from Continuing Operations of $31.5 million as of Q3 2025, which was up 162.93% from $12.0 million recorded in Q2 2025.
  • Collegium Pharmaceutical's 5-year Income from Continuing Operations high stood at $72.8 million for Q2 2021, and its period low was -$25.0 million during Q4 2021.
  • Over the past 3 years, Collegium Pharmaceutical's median Income from Continuing Operations value was $13.0 million (recorded in 2023), while the average stood at $14.8 million.
  • The largest annual percentage gain for Collegium Pharmaceutical's Income from Continuing Operations in the last 5 years was 7,577.45% (2021), contrasted with its biggest fall of 459.79% (2021).
  • Quarterly analysis of 5 years shows Collegium Pharmaceutical's Income from Continuing Operations stood at -$25.0 million in 2021, then spiked by 71.24% to -$7.2 million in 2022, then surged by 543.67% to $31.9 million in 2023, then slumped by 60.75% to $12.5 million in 2024, then soared by 237.51% to $31.5 million in 2025.
  • Its last three reported values are $31.5 million in Q3 2025, $12.0 million for Q2 2025, and $2.4 million during Q1 2025.